Found 7 matching trials
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
PHASE3A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safet...
Location
Beijing Tsinghua Changgung Hospital
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
PHASE1A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics i...
Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers
PHASE11. To evaluate the pharmacokinetics (PK) and relative bioavailability of TG...
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (Β± Ribavirin) in HCV Genotype I Infected Patients
PHASE2A phase II study to evaluate the efficacy and safety in TG-2349 combination...
Location
Peking University Peoples Hospital
To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers
PHASE1To evaluate the drug-drug reactions between TG-2349 and DAG181, and the pha...
Location
Xiangya Hospital Central South University
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
PHASE2A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evalu...
Location
Kaohsiung Medical University Chung-Ho Memorial Hospital
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349
PHASE1The purpose of this study is to evaluate the safety, tolerability, and phar...
Location
Xiangya Hospital Central South University